Christopher O’Donnell
Member of Technical Advisory BoardDr. Christopher O’Donnell, Ph.D., also known as Chris, is Director of Cartography Biosciences, Inc. from February 2026. Dr. O’Donnell serves as Member of Technical Advisory Board for Pyxis Oncology, Inc. since April 2022. He has been Director at Strata Oncology, Inc. since May 2021. Dr. O’Donnell serves as a Director of Arkuda Therapeutics, Inc. He served as an Board Observer at BioAtla, Inc. since 2020. He served as an Independent Director at TRex Bio, Inc. since January 2026. He has been Director at Arrakis Therapeutics, Inc. since December 2021. He served as Vice President, WWBD & Partner at Pfizer Venture Investments LLC until April 2026. He served as Executive Director & Principal at Pfizer Venture Investments LLC. He served as Independent Director of Pyxis Oncology, Inc. since March 2021. He is an Executive Director of Worldwide Research, Development & Medical (WRD) and Principal at Pfizer Ventures. He had been Independent Director of Kymera Therapeutics, Inc. (Kymera Therapeutics LLC) since May 2019 until August 20, 2020. Within Pfizer Ventures, Dr. O’Donnell is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. Dr. O’Donnell has scientific leadership at Pfizer and a strong track record of delivering clinical candidates across multiple disease areas and modalities. Prior to Pfizer, Dr. O’Donnell built and led the Applied Synthesis Technologies group within Pfizer Worldwide Research & Development Organization to accelerate the delivery of Pfizer’s small molecule portfolio. Dr. O’Donnell also built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in seven conjugates entering clinical development for many different cancer indications. Dr. O’Donnell started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates, with the most advanced being the AMPA positive allosteric modulator in Phase 2 that was licensed to Biogen. Dr. O’Donnell has co-authored 55 peer reviewed manuscripts and is the inventor/co-inventor on 25 patents. Dr. O’Donnell serves on the boards of directors of several privately held companies, including Adapsyn Biosciences and Storm Therapeutics and is a board observer on numerous other privately held companies. Dr. O’Donnell briefly served as a board observer on Morphic Therapeutic prior to their entry into the public market, Mitokinin, Strata Oncology and Petra Therapeutics. Dr. O’Donnell earned his B.S. in Chemistry from the University of Illinois-Urbana/Champaign and his Ph.D. in Chemistry from the University of Wisconsin-Madison and joined Pfizer after his post-doctoral research studies as an American Cancer Society Fellow at the University of California—Irvine.
Positions
- Company NamePyxis Oncology, Inc.Stock CodePYXSPositionMember of Technical Advisory BoardColleagues
- TCThomas CivikCEO & Chairman
- JWJitendra WadhaneChief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer
- BNBalu N. BalasubramanianInterim Chief Technology Officer
- DRDonna RegaladoHead of Human Resources
- CTCharles T. GombarSenior Vice President of Portfolio & Program Management
- JLJohn L. FlavinLead Independent Director
- DSDarren S. ClineIndependent Director
- MRMorris RosenbergChairperson of Technical Advisory Board
